Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases. - Archive ouverte HAL Access content directly
Journal Articles BMC Cancer Year : 2013

Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases.

(1) , (2) , (3) , (4) , (5) , (6, 7) , (8) , (1) , (1) , (3) , (9) , (1)
1
2
3
4
5
6
7
8
9

Abstract

BACKGROUND: The Follicle Stimulating Hormone receptor (FSHR) is expressed by the vascular endothelium in a wide range of human tumors. It was not determined however if FSHR is present in metastases which are responsible for the terminal illness. METHODS: We used immunohistochemistry based on a highly FSHR-specific monoclonal antibody to detect FSHR in cancer metastases from 6 major tumor types (lung, breast, prostate, colon, kidney, and leiomyosarcoma ) to 6 frequent locations (bone, liver, lymph node, brain, lung, and pleura) of 209 patients. RESULTS: In 166 patients examined (79%), FSHR was expressed by blood vessels associated with metastatic tissue. FSHR-positive vessels were present in the interior of the tumors and some few millimeters outside, in the normally appearing tissue. In the interior of the metastases, the density of the FSHR-positive vessels was constant up to 7 mm, the maximum depth available in the analyzed sections. No significant differences were noticed between the density of FSHR-positive vessels inside vs. outside tumors for metastases from lung, breast, colon, and kidney cancers. In contrast, for prostate cancer metastases, the density of FSHR-positive vessels was about 3-fold higher at the exterior of the tumor compared to the interior. Among brain metastases, the density of FSHR-positive vessels was highest in lung and kidney cancer, and lowest in prostate and colon cancer. In metastases of breast cancer to the lung pleura, the percentage of blood vessels expressing FSHR was positively correlated with the progesterone receptor level, but not with either HER-2 or estrogen receptors. In normal tissues corresponding to the host organs for the analyzed metastases, obtained from patients not known to have cancer, FSHR staining was absent, with the exception of approx. 1% of the vessels in non tumoral temporal lobe epilepsy samples. CONCLUSION: FSHR is expressed by the endothelium of blood vessels in the majority of metastatic tumors.
Fichier principal
Vignette du fichier
1471-2407-13-246.pdf (3.03 Mo) Télécharger le fichier
Vignette du fichier
1471-2407-13-246.xml (62.45 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other
Loading...

Dates and versions

inserm-00825697 , version 1 (24-05-2013)

Identifiers

Cite

Ahsan Siraj, Virginie Desestret, Martine Antoine, Gaëlle Fromont, Michel Huerre, et al.. Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases.. BMC Cancer, 2013, 13 (1), pp.246. ⟨10.1186/1471-2407-13-246⟩. ⟨inserm-00825697⟩
561 View
494 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More